Teleflex (NYSE:TFX) Cut to "Hold" at StockNews.com

Teleflex (NYSE:TFX - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Friday.

Several other research analysts have also recently issued reports on the stock. Wells Fargo & Company cut their target price on shares of Teleflex from $214.00 to $146.00 and set an "equal weight" rating on the stock in a report on Friday. Mizuho dropped their target price on shares of Teleflex from $275.00 to $250.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Citizens Jmp downgraded Teleflex from an "outperform" rating to a "market perform" rating in a report on Thursday, February 27th. Needham & Company LLC reiterated a "hold" rating on shares of Teleflex in a report on Monday, December 16th. Finally, Piper Sandler reissued a "neutral" rating and set a $140.00 target price (down from $255.00) on shares of Teleflex in a research note on Friday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $181.43.

Teleflex Trading Down 3.2 %

Shares of TFX traded down $4.26 during mid-day trading on Friday, reaching $130.87. The company's stock had a trading volume of 1,523,458 shares, compared to its average volume of 799,458. The stock has a market cap of $6.08 billion, a PE ratio of 26.02, a P/E/G ratio of 1.73 and a beta of 1.16. The company's fifty day moving average price is $174.58 and its two-hundred day moving average price is $203.93. Teleflex has a 52 week low of $128.55 and a 52 week high of $249.90. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $795.40 million for the quarter, compared to analysts' expectations of $813.24 million. On average, analysts predict that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Trading of Teleflex

Hedge funds and other institutional investors have recently modified their holdings of the business. Apollon Wealth Management LLC boosted its stake in Teleflex by 3.7% during the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company's stock worth $377,000 after acquiring an additional 55 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Teleflex by 0.3% in the 3rd quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company's stock worth $4,844,000 after purchasing an additional 60 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Teleflex by 0.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 15,332 shares of the medical technology company's stock worth $3,792,000 after buying an additional 65 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Teleflex by 4.5% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,517 shares of the medical technology company's stock valued at $375,000 after buying an additional 66 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in Teleflex by 1.7% during the third quarter. HighTower Advisors LLC now owns 3,998 shares of the medical technology company's stock valued at $986,000 after buying an additional 66 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.